The strong organic growth, improved profitability, and robust 2026 guidance suggest Bioventus is successfully executing its strategy. Traders should monitor the execution of this guidance, particularly the margin expansion and cash flow generation, which could support further stock appreciation.
Price Chart
Executive Summary
Bioventus reported strong Q4 2025 results with $157.9M revenue (2.8% YoY growth, 10% organic growth) and GAAP EPS of $0.21, reversing a prior-year loss. The company achieved $38M in operating cash flow (97% increase) and issued 2026 guidance projecting $600-610M revenue and $0.73-0.77 Adjusted EPS, indicating continued growth momentum.
Key Financial Metrics
Key Facts
- Q4 revenue: $157.9M (+2.8% YoY, +10% organic)
- Q4 GAAP EPS: $0.21 (vs. $0.00 prior year)
- Q4 cash from operations: $38M (+97% YoY)
- 2026 guidance: $600-610M revenue (+6-7%), $0.73-0.77 Adjusted EPS (+7-13%)
- Full-year 2025 revenue: $568.1M (-0.9% YoY, +7.5% organic)
Financial Impact
Q4 revenue increased by $4.3M YoY, with 2026 revenue guidance projecting $32-42M growth over 2025. Adjusted EPS is expected to grow by $0.05-0.09 in 2026.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Pain Treatments | $79.7M | +15.1% |
| Surgical Solutions | $55.5M | +3.4% |
| Restorative Therapies | $22.7M | -26.0% |
Risk Factors
- The prior-year revenue comparison was affected by the divestiture of the Advanced Rehabilitation Business, which could distort YoY growth metrics.
- The company's Adjusted EPS guidance increase (7-13%) is modest compared to the significant improvement from 2024 to 2025 (from -$0.56 to $0.68).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001665988-26-000010 |
| Document: bvs-20260305.htm | 0001665988-26-000010 |
| Document: 0001665988-26-000010-index-headers.html | 0001665988-26-000010 |
| Document: 0001665988-26-000010-index.html | 0001665988-26-000010 |
| Document: 0001665988-26-000010.txt | 0001665988-26-000010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $13.88 $13.16 | ▼ −5.19% | ▼ −3.66% | $13.13 (−5.40%) |
Aug 5, 2026 8w ago | 8-K | $15.26 $14.37 | ▼ −5.83% | ▼ −5.23% | $13.13 (−13.96%) |
Aug 5, 2026 8w ago | Press Release | $15.26 $14.37 | ▼ −5.83% | ▼ −5.23% | $13.13 (−13.96%) |
Jun 11, 2026 16w ago | Institutional Cluster | $8.68 $12.22 | ▼ −40.78% | ▼ −38.89% | $13.13 (−51.27%) |
Jun 2, 2026 17w ago | Press Release | $8.11 $9.85 | ▼ −21.45% | ▼ −23.02% | $13.13 (−61.90%) |
May 21, 2026 19w ago | 8-K | $9.28 $8.99 | ▼ −3.13% | ▼ −1.71% | $13.13 (+41.49%) |
May 8, 2026 21w ago | Court Ruling | $10.50 $9.04 | ▼ −13.90% | ▼ −13.93% | $13.13 (+25.05%) |
May 6, 2026 21w ago | 8-K | $10.92 $8.55 | ▼ −21.70% | ▼ −24.48% | $13.13 (+20.24%) |
May 6, 2026 21w ago | Press Release | $10.92 $8.55 | ▼ −21.70% | ▼ −24.48% | $13.13 (+20.24%) |
Apr 28, 2026 22w ago | Press Release | $9.67 $8.87 | ▼ −8.27% | ▼ −14.32% | $13.13 (+35.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access